EVALUATION OF NO EVIDENCE OF PROGRESSION OR ACTIVE DISEASE (NEPAD) IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN THE ORATORIO TRIAL

被引：0
|
作者：
Wolinsky, Jerry [1 ]
Montalban, Xavier [2 ]
Kappos, Ludwig [3 ]
Hauser, Stephen [4 ]
Giovannoni, Gavin [5 ]
de Seze, Jerome [6 ]
Bar-Or, Amit [7 ]
Masterman, Donna [8 ]
Bernasconi, Corrado [9 ]
Wei, Wei [9 ]
Garren, Hideki [9 ]
Chin, Peter [8 ]
Belachew, Shibeshih [9 ]
Arnold, Doug L. [10 ,11 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Univ Hosp, Basel, Switzerland
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Queen Mary Univ London, London, England
[6] Univ Hosp Strasbourg, Strasbourg, France
[7] Univ Penn, Philadelphia, PA 19104 USA
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
[10] McGill Univ, Montreal, PQ, Canada
[11] NeuroRx Res, Montreal, PQ, Canada
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2017年 / 88卷 / 05期
关键词：
D O I：
10.1136/jnnp-2017-316074.83
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
83
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Multimodal Evoked Potentials in Primary Progressive Multiple Sclerosis: Identification of Patients at Risk for Disease Progression
    Hardmeier, M.
    Schlaeger, R.
    Lascano, A.
    Toffolet, L.
    Schindler, C.
    Gobbi, C.
    D'epinay, P. Lalive
    Kuhle, J.
    Kappos, L.
    Fuhr, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 330 - 330
  • [22] Primary Progressive Multiple Sclerosis-A Key to Understanding and Managing Disease Progression
    Sempik, Izabela
    Dziadkowiak, Edyta
    Moreira, Helena
    Zimny, Anna
    Pokryszko-Dragan, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [23] Disease activity has a significant impact in progression of primary progressive multiple sclerosis
    Marrodan, M.
    Bensi, C.
    Pappolla, A.
    Rojas, J. I.
    Patrucco, L.
    Farez, M. F.
    Cristiano, E.
    Correale, J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 382 - 382
  • [24] Evaluation of the times of disability progression and related factors in patients with primary progressive multiple sclerosis from Argentina
    Alonso, Ricardo
    Garcea, Orlando
    Ignacio Rojas, Juan
    Alonso, Marina
    Lazaro, Luciana
    Lopez, Pablo
    Casas, Magdalena
    Tkachuk, Veronica
    Steinberg, Judith
    Barboza, Andres
    Martinez, Alejandra
    Ysrraelit, Celica
    Correale, Jorge
    Marrodan, Mariano
    Chertcoff, Anibal
    Deri, Norma
    Miguez, Jimena
    Patrucco, Liliana
    Cristiano, Edgardo
    Pestchanker, Claudia
    Silva, Emanuel
    Vrech, Carlos
    Zanga, Gisela
    Leguizamon, Felisa
    Carnero Contentti, Edgar
    Carra, Adriana
    Mainella, Carolina
    Anabel Silva, Berenice
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [25] A Functional Composite Endpoint to Characterize Disease Progression in Patients with Active or Non-active Secondary Progressive Multiple Sclerosis
    Kappos, Ludwig
    Cree, Bruce A. C.
    Bar-Or, Amit
    Gold, Ralf
    Vermersch, Patrick
    Fox, Robert J.
    Benedict, Ralph
    Arnould, Sophie
    Karlsson, Goeril
    Meier, Daniela Piani
    Dahlke, Frank
    Hach, Thomas
    Giovannoni, Gavin
    NEUROLOGY, 2021, 96 (15)
  • [26] A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis
    Kita, M
    Goodkin, DE
    Bacchetti, P
    Stone, J
    Waubant, E
    Pelletier, D
    Nelson, SJ
    NEUROLOGY, 2000, 54 (07) : A22 - A23
  • [27] A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis
    Kita, M
    Cohen, JA
    Fox, RJ
    Evangelista, A
    Pelletier, D
    Stone, J
    Goodkin, DE
    Zamvil, SS
    NEUROLOGY, 2004, 62 (07) : A99 - A99
  • [28] A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis
    Kita, M
    Pelletier, D
    Goodkin, D
    Fox, R
    Cohen, J
    Bacchetti, P
    Stone, J
    Hietpas, J
    Zamvil, S
    NEUROLOGY, 2001, 56 (08) : A149 - A149
  • [29] EFFECT OF OCRELIZUMAB ON UPPER LIMB FUNCTION IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) IN THE ORATORIO STUDY (ENCORE)
    Fox, Edward
    Markowitz, Clyde
    Applebee, Angela
    Montalban, Xavier
    Wolinsky, Jerry S.
    Belachew, Shebeshih
    Fiore, Damian
    Han, Jian
    Musch, Bruno
    Giovannoni, Gavin
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E14 - E14
  • [30] Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis?
    Rudick, R
    MULTIPLE SCLEROSIS, 2003, 9 (02): : 210 - 212
12345